Dsam Partners Llp Has Trimmed Its Banco Macro Sa (BMA) Position by $3.18 Million; Stock Price Rose; Essex Woodlands Health Ventures Lowered Abiomed (ABMD) Position by $84.53 Million

January 17, 2018 - By Marie Mckinney

Essex Woodlands Health Ventures Inc decreased its stake in Abiomed Inc (ABMD) by 34.7% based on its latest 2017Q3 regulatory filing with the SEC. Essex Woodlands Health Ventures Inc sold 503,182 shares as the company’s stock rose 15.32% with the market. The hedge fund held 946,818 shares of the health care company at the end of 2017Q3, valued at $159.63 million, down from 1.45 million at the end of the previous reported quarter. Essex Woodlands Health Ventures Inc who had been investing in Abiomed Inc for a number of months, seems to be less bullish one the $9.87B market cap company. The stock increased 2.40% or $5.23 during the last trading session, reaching $223.32. About 243,062 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since January 17, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.

Guy Shahar decreased its stake in Banco Macro Sa (BMA) by 11.37% based on its latest 2017Q3 regulatory filing with the SEC. Dsam Partners Llp sold 27,211 shares as the company’s stock rose 7.03% with the market. The hedge fund run by Guy Shahar held 212,205 shares of the commercial banks company at the end of 2017Q3, valued at $24.90 million, down from 239,416 at the end of the previous reported quarter. Dsam Partners Llp who had been investing in Banco Macro Sa for a number of months, seems to be less bullish one the $8.29 billion market cap company. The stock increased 0.76% or $0.88 during the last trading session, reaching $116.38. About 156,021 shares traded. Banco Macro S.A. (NYSE:BMA) has risen 43.80% since January 17, 2017 and is uptrending. It has outperformed by 27.10% the S&P500.

Dsam Partners Llp, which manages about $718.15M US Long portfolio, upped its stake in Baidu Inc (NASDAQ:BIDU) by 111,317 shares to 124,622 shares, valued at $30.87 million in 2017Q3, according to the filing. It also increased its holding in Ishares Tr (FXI) by 44,913 shares in the quarter, for a total of 96,172 shares, and has risen its stake in Altaba Inc.

Analysts await Banco Macro S.A. (NYSE:BMA) to report earnings on February, 21. They expect $2.69 earnings per share, up 43.09% or $0.81 from last year’s $1.88 per share. BMA’s profit will be $191.50M for 10.82 P/E if the $2.69 EPS becomes a reality. After $2.24 actual earnings per share reported by Banco Macro S.A. for the previous quarter, Wall Street now forecasts 20.09% EPS growth.

Among 5 analysts covering Banco Macro SA (NYSE:BMA), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Banco Macro SA had 7 analyst reports since February 9, 2016 according to SRatingsIntel. The stock has “Buy” rating by Goldman Sachs on Monday, September 26. The company was downgraded on Monday, September 11 by Goldman Sachs. As per Tuesday, June 13, the company rating was upgraded by Credit Suisse. The firm earned “Neutral” rating on Tuesday, March 29 by Credit Suisse. On Monday, May 23 the stock rating was upgraded by Citigroup to “Neutral”. The firm earned “Neutral” rating on Wednesday, June 1 by UBS.

Among 12 analysts covering Abiomed (NASDAQ:ABMD), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Abiomed had 26 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Wednesday, August 5 by Northland Capital. As per Thursday, December 21, the company rating was maintained by Jefferies. The rating was reinitiated by William Blair on Thursday, June 8 with “Buy”. The company was initiated on Friday, September 29 by SunTrust. The rating was maintained by BTIG Research with “Hold” on Tuesday, August 4. Jefferies maintained the shares of ABMD in report on Thursday, June 29 with “Buy” rating. On Wednesday, December 7 the stock rating was initiated by Guggenheim with “Buy”. The firm has “Outperform” rating given on Wednesday, May 4 by Leerink Swann. PiperJaffray upgraded the shares of ABMD in report on Thursday, April 6 to “Overweight” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Thursday, September 21 by Jefferies.

Since July 31, 2017, it had 0 buys, and 5 sales for $9.51 million activity. 982 shares valued at $142,554 were sold by ROSE ERIC A MD on Wednesday, August 30. $1.91M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by Greenfield Andrew J. 16,500 shares were sold by Weber David M, worth $2.44M on Monday, July 31.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on January, 25. They expect $0.50 EPS, up 47.06% or $0.16 from last year’s $0.34 per share. ABMD’s profit will be $22.11M for 111.66 P/E if the $0.50 EPS becomes a reality. After $0.44 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 13.64% EPS growth.

Investors sentiment decreased to 1.3 in Q3 2017. Its down 0.13, from 1.43 in 2017Q2. It worsened, as 27 investors sold ABMD shares while 89 reduced holdings. 55 funds opened positions while 96 raised stakes. 38.51 million shares or 1.21% less from 38.99 million shares in 2017Q2 were reported. 1,189 were reported by Walleye Trading Limited Liability Corp. Eaton Vance Mngmt reported 44,371 shares or 0.02% of all its holdings. Dorsey & Whitney Tru Llc, South Dakota-based fund reported 1,276 shares. Polar Cap Llp holds 210,000 shares or 0.4% of its portfolio. Advsrs Asset Management Inc owns 17,968 shares or 0.05% of their US portfolio. Biondo Inv Advsrs Ltd Limited Liability Company has invested 3.09% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Tci Wealth Advsrs holds 44 shares or 0% of its portfolio. Country Trust Comml Bank holds 0.76% in ABIOMED, Inc. (NASDAQ:ABMD) or 99,652 shares. Principal invested in 178,768 shares or 0.03% of the stock. Ci Glob Invs holds 0% or 65 shares. Us Fincl Bank De has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). Utah Retirement owns 7,500 shares or 0.03% of their US portfolio. Bluestein R H Com has invested 0.22% in ABIOMED, Inc. (NASDAQ:ABMD). Pnc Fin Svcs Group accumulated 0% or 9,019 shares. Financial Bank Of America Corp De reported 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: